Adolescent patient achieved a 2-point improvement in IGA

Click and drag
to see results

Actual 12-year-old patient in the phase 3 adolescent DUPIXENT trial. Patient had a baseline IGA of 4 and EASI of 31. Individual results may vary.

A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point improvement from baseline1

  • This adolescent patient did not meet the primary endpoint in the clinical trial based on their IGA score at Week 16

Significant skin clearance was demonstrated in adolescents (primary endpoint; P<0.001)1-3,a

Efficacy Results of DUPIXENT at Week 16 (FAS)
Achieved clear or almost‑clear skin (IGA 0 or 1) 24% 2%

aResponder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2 points on a 0‑4 scale at Week 16 (primary efficacy outcome).

bAdolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose.1